Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MW031 in PMO Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMD -4.0\<T-score ≤-2.5 at either the lumbar spine or total hip or femoral neck~* All subjects must have at least one of following additional the risk factors:history of fracture, parental history of hip fracture, increased bone turnover rate at screening, low body weight, elderly (age≥65year)，current smoker~* Postmenopausal is defined as \>2 years postmenopausal, which can be \>2 years of spontaneous amenorrhea, or bilateral oophorectomy \>2 years after surgery. If bilateral oophorectomy status is unknown, use follicle-stimulating hormone (FSH) levels \> 40 mIU/mL to confirm surgical postmenopausal status.~Exclusion Criteria:~* Bone/metabolic disease~* Hyperparathyroidism or hypoparathyroidism~* Thyroid condition: Hyperthyroidism or hypothyroidism~* Rheumatoid arthritis~* Malignant tumors~* Malabsorption syndrome~* Oral bisphosphonates

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MW031 (Type: EXPERIMENTAL): MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
- placebo (Type: PLACEBO_COMPARATOR): Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).